Literature DB >> 15007305

Renal-tubule metabolism of ifosfamide to the nephrotoxic chloroacetaldehyde: pharmacokinetic modeling for estimation of intracellular levels.

Katarina Aleksa1, Shinya Ito, Gideon Koren.   

Abstract

Ifosfamide (IF) improves survival in children with solid tumors but causes a high rate of nephrotoxicity. We hypothesized that this is caused by an oxidative metabolite of IF, chloroacetaldehyde, which is produced locally by the cells of the renal tubule (RT). For this hypothesis to be viable, one must document that chloroacetaldehyde concentrations in the RT cell are consistent with levels shown to cause nephrotoxicity in experimental systems. Using pharmacokinetic modeling of experimental data, we show that the median level of chloroacetaldehyde in RT cells is 80 micromol/L, ranging from 35 to 320 micromol/L. These concentrations are consistent with levels shown experimentally to cause functional and structural RT damage and lends validity to the hypothesis that local renal production of chloroacetaldehyde causes nephrotoxicity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15007305     DOI: 10.1016/j.lab.2003.10.013

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  9 in total

Review 1.  Drug-induced acute kidney injury in children.

Authors:  Lauren N Faught; Michael J E Greff; Michael J Rieder; Gideon Koren
Journal:  Br J Clin Pharmacol       Date:  2015-06-01       Impact factor: 4.335

2.  Hydroxylation and N-dechloroethylation of Ifosfamide and deuterated Ifosfamide by the human cytochrome p450s and their commonly occurring polymorphisms.

Authors:  Diane M Calinski; Haoming Zhang; Susan Ludeman; M Eileen Dolan; Paul F Hollenberg
Journal:  Drug Metab Dispos       Date:  2015-05-01       Impact factor: 3.922

3.  Mesna or cysteine prevents chloroacetaldehyde-induced cell death of human proximal tubule cells.

Authors:  Gerald Schwerdt; Antje Kirchhoff; Ruth Freudinger; Brigitte Wollny; Andreas Benesic; Michael Gekle
Journal:  Pediatr Nephrol       Date:  2007-02-02       Impact factor: 3.714

4.  Cytochrome P450 3A and 2B6 in the developing kidney: implications for ifosfamide nephrotoxicity.

Authors:  Katarina Aleksa; Doug Matsell; Kris Krausz; Harry Gelboin; Shinya Ito; Gideon Koren
Journal:  Pediatr Nephrol       Date:  2005-05-04       Impact factor: 3.714

5.  Pharmacogenomics in Children.

Authors:  Michael J Rieder; Abdelbaset A Elzagallaai
Journal:  Methods Mol Biol       Date:  2022

6.  Ifosfamide toxicity in cultured proximal renal tubule cells.

Authors:  James Springate; Mary Taub
Journal:  Pediatr Nephrol       Date:  2006-10-27       Impact factor: 3.714

7.  In vivo mesna and amifostine do not prevent chloroacetaldehyde nephrotoxicity in vitro.

Authors:  Zeinab Yaseen; Christian Michoudet; Gabriel Baverel; Laurence Dubourg
Journal:  Pediatr Nephrol       Date:  2008-01-18       Impact factor: 3.714

8.  Role of MGMT in protecting against cyclophosphamide-induced toxicity in cells and animals.

Authors:  Ryan J Hansen; Susan M Ludeman; Sari J Paikoff; Anthony E Pegg; M Eileen Dolan
Journal:  DNA Repair (Amst)       Date:  2007-05-07

9.  Early and late adverse renal effects after potentially nephrotoxic treatment for childhood cancer.

Authors:  Esmee Cm Kooijmans; Arend Bökenkamp; Nic S Tjahjadi; Jesse M Tettero; Eline van Dulmen-den Broeder; Helena Jh van der Pal; Margreet A Veening
Journal:  Cochrane Database Syst Rev       Date:  2019-03-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.